A Phase 1/2 interventional study of Therapeutic hepatitis B vaccine and Commercial Hepatitis B vaccine in Chronic Hepatitis b, sponsored by Vaxine Pty Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Vaxine Pty Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Hepatitis B, Chronic with a site in Australia — 3 open to participants now, 5 under way, none of them phase 3. Hepatitis B, Chronic · Australia.
Among the 52 studies in Hepatitis B, Chronic with a site in Australia, this one is the 36th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 28th registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 52 studies in Hepatitis B, Chronic with a site in Australia are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Australia, China, Japan and 3 more countries
Ages 18–65
Epigenic Therapeutics, Inc · Sites in Australia, China, New Zealand
Ages 18–65
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 17 · Phase 3 14 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 660 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 88 across the 47 interventional studies, 300 across the 4 observational. Of the 44 that completed or were terminated, 24 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 52 have an industry lead sponsor. The 10 most frequent:
Vaxine Pty Ltd is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Vaxine Pty Ltd has 1 study filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
4 of the studies in Hepatitis B, Chronic with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03038802Vaxine Pty LtdA Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection | 2027-03-01 |
| NCT07059403Chimivac INCA Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults | 2027-04 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
| NCT06661148Epigenic Therapeutics, IncStudy of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 52 studies in Hepatitis B, Chronic with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot study to determine the safety and efficacy of a novel adjuvanted hepatitis B virus (HBV) vaccine formulated as a potential therapeutic vaccine against chronic HBV infection. An ongoing human clinical trial of this HBV vaccine in a prophylactic setting has confirmed this vaccine to be more effective at inducing seroconversion as measured by development of Hepatitis B surface antibody (HBsAb) in poor responder subjects than the standard alum-adjuvanted HBV vaccine, providing promise that this new vaccine may also be able to induce HBV viral control and/or seroconversion in chronically infected subjects
Prophylactic immunisation with HBsAg-based vaccines leads to development of HBsAg antibodies that provide protection against HBV infection. Modern HBV vaccines are based on recombinant HBsAg produced by expression in yeast expression systems. For infants whose mothers are HBsAg positive, the first HBV vaccine dose is given at birth and three further doses are administrated during the following 12 months at 2, 4 and 6 or 12 months. Studies have shown that these HBV vaccines are 90 to 95% effective in preventing children from developing chronic infection if they have not yet been infected. Since 1982 over one billion doses of HBV vaccine have been used worldwide. However a number of groups have poor responses to the existing HBV vaccines and these include older adults (age > 40) and patients with immunodeficiency, diabetes or renal impairment. A pilot clinical study demonstrated that standard anti-HBV vaccination could reduce HBV replication in 50% of chronic carriers. A multicentre trial, showed both the efficacy and the limitations of this approach. This study included 118 treatment-naive patients, with detectable serum HBV DNA using a standard liquid hybridization study and biopsy-proven chronic hepatitis pre-vaccination. Over a 12-month period, they were given either five intradermal injections of 20 µg of a pre S2:S HBV vaccine (GenHevac B.Pasteur-Merieux) or a standard HBV vaccine (Recombivax, MSD) or no treatment. Three months after the first three vaccine injections, the percentage of serum HBV DNA negativity was higher in the vaccine groups (15.5%) than in the control group (2.7%). After 1 year follow-up and five vaccine injections, there was no difference in the rate of serum HBV DNA negativity, but those receiving HBV vaccines had significantly decreased HBV viral load between 6 and 12 months when compared to the control group. The rate of HBe:anti-HBe seroconversion did not differ between the vaccinated and unvaccinated groups, but early HBeAg negativity and anti-HBe detection after 6 months of follow-up was seen only in vaccinated patients (8 and 15% in groups B (Recombivax.) and C (GenHevac B.), respectively, compared with 0% in the controls). Analysis of the vaccine-induced immune responses in 40 patients with HBV chronic hepatitis during this vaccine trial showed that vaccination elicited T cell proliferative responses in 7 of 27 patients who received the vaccine versus none of the unvaccinated control group. These specific responses for envelope antigen were mediated by CD4 T cells that produced high levels of gamma interferon. The reduction of serum HBV-DNA in some of these patients suggests that induction of CD4 T cell responses could be important in controlling viremia after vaccine therapy of HBV chronic carriers.
Experiments in transgenic mice that constitutively express HBV in the liver as a model of asymptomatic chronic HBV carriers have shown that immunization can overcome functional tolerance to HBV by inducing a specific antiviral immune response. The study vaccine was tested for its ability to induce seroconversion in a HBV transgenic mouse model. The results confirmed that the vaccine induced a high titre of anti-HBsAg antibodies and suppressed HBV virus load in the liver. Importantly from a safety perspective no evidence of a flare in liver disease as reflected by elevation of liver functions tests, was seen despite evidence the vaccine suppressed liver virus. The vaccinated mice had the lowest levels of liver transaminases, consistent with the vaccine reducing virus-mediated damage to the liver.
This study will test the hypothesis that the investigational vaccine will boost HBV antibody and T cell responses in chronically infected patients and thereby improve HBV viral control and opportunity for seroconversion. As this is an exploratory study, subjects with chronic HBV infection will be enrolled whether or not they are on current antiviral treatment. This will then allow comparison of vaccine effects in subjects on and off concomitant antiviral treatment, with this data used to assist the design of future studies. The study will test the hypothesis that a potent preS HBV vaccine including Advax adjuvant will enhance both humoral and cellular immunity thereby helping to control chronic hepatitis B infection. The ultimate goal is to induce HBsAg seroconversion and effect permanent clearance of HBV or at a minimum to enable better immune control of viral replication. This pilot study will collect preliminary data on the safety and efficacy of this vaccine approach in chronically HBV infected individuals, as a precursor to larger efficacy studies in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
Biological: Commercial Hepatitis B vaccine
Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
Biological: Therapeutic hepatitis B vaccine
HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
Also known as: Hepadvax(TM)
Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
Also known as: Engerix B
Safety assessment: Frequency of vaccine-related adverse events relative to active comparator vaccine
Frequency of vaccine-related adverse events relative to active comparator vaccine
Time frame: 12 months post immunisation
Viral load
Suppression of HBV viral load
Time frame: 1 and 12 months post final immunisation
Seroconversion
Seroconversion to e antigen (if anti HBe negative at baseline) and seroconversion to surface antigen
Time frame: 1 and 12 months post final immunisation
T-cell response
Development of memory T-cell responses to HBV
Time frame: 1 and 12 months post final immunisation
B cell response
Development of memory B-cell responses to HBV
Time frame: 1 and 12 months post final immunisation
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vaxine Pty Ltd